Abstract: Disclosed herein are immunomodulatory fusion proteins comprising an IL-2; an IL-12, a collagen-binding domain, and a linear polypeptide spacer, methods of making and using the same. The immunomodulatory fusion proteins disclosed herein are useful for the treatment of cancer.

Abstract: A method and a dynamic Static Random Access Memory (SRAM) circuit for implementing single bit redundancy with any bit decode, and a design structure on which the subject circuit resides are provided. The SRAM circuit includes a plurality of bitline columns and a pair of redundancy columns respectively coupled to a respective merged bit column select and redundancy steering multiplexer. Each merged bit column select and redundancy steering multiplexer receives a respective select signal input. A select signal generation circuit receives a redundancy steering signal and a respective one-hot bit select signal, generating the respective select signal input.

Abstract: A method and a dynamic Static Random Access Memory (SRAM) circuit for implementing single bit redundancy with any bit decode, and a design structure on which the subject circuit resides are provided. The SRAM circuit includes a plurality of bitline columns and a pair of redundancy columns respectively coupled to a respective merged bit column select and redundancy steering multiplexer. Each merged bit column select and redundancy steering multiplexer receives a respective select signal input. A select signal generation circuit receives a redundancy steering signal and a respective one-hot bit select signal, generating the respective select signal input.

Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.

Abstract: The invention discloses methods of treatment of tumors that express oncogenic forms of the epidermal growth factor receptor (EGFR), such as EGFRvIII. The methods include testing of cancer patients for expression of EGFRvIII in their tumors, followed by treatment with a protein that contains antibody variable regions that recognize specific epitopes on the surface of the EGFR.

Abstract: Antibodies and polypeptides that bind to and/or modulate the activity of receptors in the epidermal growth factor family are provided herein.

Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.

Abstract: The invention relates in part to methods of making single-domain antibodies and methods of using single-domain antibodies to diagnose and treat disease. The invention also relates to methods and products for modulating target protein activity, including methods to inhibit huntingtin protein aggregation in Huntington's disease. The invention also includes methods and compounds for identifying pharmaceutical agents for preventing and treating diseases and for monitoring the efficacy of treatments for target protein-associated diseases.

Abstract: Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) ?-hydroxylase are provided. The anti-aspartyl (asparaginyl) ?-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) ?-hydroxylase.

Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.

Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.